Suppression of pathological ocular neovascularization by a small molecule, SU1498

Autor: Yao Jin, Li Jing-Jing, Tao Shu-Ya, Zhang Qiu-Yang, Yan Biao

Publikováno v: Biomedicine & Pharmacotherapy, Vol 128, Iss, Pp 110248-(2020)

Selective inhibition of vascular endothelial growth factor receptor (VEGFR), particularly VEGFR-2, is an efficient method for the treatment of ocular neovascularization. SU1498 is a specific inhibitor of VEGFR-2. In this study, we investigated the ro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce4f7d4a6ffa68df5db6c68ad0e023f5
https://pubmed.ncbi.nlm.nih.gov/32454287

Osthole: A Traditional Chinese Medicine for Ocular Anti-Angiogenic Therapy.

Autor: Zhang QY; The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China., Tao SY; The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China., Lu C; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China., Li JJ; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China., Li XM; The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China., Jiang Q; The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.; The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing, China., Yan B; Eye Institute, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China, biao.yan@fdeent.org.; National Health Commission (NHC) Key Laboratory of Myopia and Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China, biao.yan@fdeent.org.; Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China, biao.yan@fdeent.org.

Publikováno v: Ophthalmic research [Ophthalmic Res] 2020; Vol. 63 (5), pp. 483-490. Date of Electronic Publication: 2020 Jan 17.